Shopping Cart 0
Cart Subtotal
AED 0

Global Targeted Drug ALK Inhibitors for NSCLC Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 17910

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 26864

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 35819

Details

Scope of the Report:

The global Targeted Drug ALK Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug ALK Inhibitors for NSCLC.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Targeted Drug ALK Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug ALK Inhibitors for NSCLC market by product type and applications/end industries.

Market Segment by Companies, this report covers

Pfizer

Novartis

Chugai Pharmaceutical (Hoffmann-La Roche group)

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Beacon Pharma Limited

Drug International Limted

Incepta Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Crizotinib

Ceritinib

Alectinib

Brigatinib

Lorlatinib

Other

Market Segment by Applications, can be divided into

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

READ MORE

Table Of Content

Scope

Table of Contents

1 Targeted Drug ALK Inhibitors for NSCLC Market Overview

1.1 Product Overview and Scope of Targeted Drug ALK Inhibitors for NSCLC

1.2 Classification of Targeted Drug ALK Inhibitors for NSCLC by Types

1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)

1.2.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Types in 2018

1.2.3 Crizotinib

1.2.4 Ceritinib

1.2.5 Alectinib

1.2.6 Brigatinib

1.2.7 Lorlatinib

1.2.8 Other

1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application

1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Squamous Cell Carcinoma of NSCLC

1.3.3 Adenocarcinoma of NSCLC

1.3.4 Large Cell Carcinoma of NSCLC

1.4 Global Targeted Drug ALK Inhibitors for NSCLC Market by Regions

1.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.5 Global Market Size of Targeted Drug ALK Inhibitors for NSCLC (2014-2024)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.3 Chugai Pharmaceutical (Hoffmann-La Roche group)

2.3.1 Business Overview

2.3.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.4 ARIAD Pharmaceuticals (Takeda)

2.4.1 Business Overview

2.4.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.5 Genvio Pharma Limited

2.5.1 Business Overview

2.5.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.6 Beacon Pharma Limited

2.6.1 Business Overview

2.6.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.7 Drug International Limted

2.7.1 Business Overview

2.7.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.8 Incepta Pharmaceuticals

2.8.1 Business Overview

2.8.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

3 Global Targeted Drug ALK Inhibitors for NSCLC Market Competition, by Players

3.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Targeted Drug ALK Inhibitors for NSCLC Players Market Share

3.2.2 Top 10 Targeted Drug ALK Inhibitors for NSCLC Players Market Share

3.3 Market Competition Trend

4 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions

4.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Regions

4.2 North America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.3 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.5 South America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

5.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

5.2 USA Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5.3 Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

6.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

6.2 Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.3 UK Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.4 France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.5 Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.6 Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

7.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

7.2 China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.3 Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.4 Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.5 India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

8.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

8.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8.4 Colombia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Targeted Drug ALK Inhibitors for NSCLC by Countries

9.1 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

9.2 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.3 UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.4 Egypt Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.5 Nigeria Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.6 South Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

10 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Type

10.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)

10.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type (2019-2024)

10.3 Crizotinib Revenue Growth Rate (2014-2024)

10.4 Ceritinib Revenue Growth Rate (2014-2024)

10.5 Alectinib Revenue Growth Rate (2014-2024)

10.6 Brigatinib Revenue Growth Rate (2014-2024)

10.7 Lorlatinib Revenue Growth Rate (2014-2024)

10.8 Other Revenue Growth Rate (2014-2024)

11 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Application

11.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)

11.2 Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Application (2019-2024)

11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)

11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)

11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)

12 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)

12.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)

12.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Regions (2019-2024)

12.3 North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.4 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.6 South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source


List Of Table

List of Tables and Figures

Figure Targeted Drug ALK Inhibitors for NSCLC Picture

Table Product Specifications of Targeted Drug ALK Inhibitors for NSCLC

Table Global Targeted Drug ALK Inhibitors for NSCLC and Revenue (Million USD) Market Split by Product Type

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Types in 2018

Figure Crizotinib Picture

Figure Ceritinib Picture

Figure Alectinib Picture

Figure Brigatinib Picture

Figure Lorlatinib Picture

Figure Other Picture

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Application (2014-2024)

Figure Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Applications in 2018

Figure Squamous Cell Carcinoma of NSCLC Picture

Figure Adenocarcinoma of NSCLC Picture

Figure Large Cell Carcinoma of NSCLC Picture

Table Global Market Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Comparison by Regions 2014-2024

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Table Pfizer Basic Information, Manufacturing Base and Competitors

Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Novartis Basic Information, Manufacturing Base and Competitors

Table Novartis Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Basic Information, Manufacturing Base and Competitors

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table ARIAD Pharmaceuticals (Takeda) Basic Information, Manufacturing Base and Competitors

Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Genvio Pharma Limited Basic Information, Manufacturing Base and Competitors

Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Beacon Pharma Limited Basic Information, Manufacturing Base and Competitors

Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Drug International Limted Basic Information, Manufacturing Base and Competitors

Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Incepta Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Players (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2017

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2018

Figure Global Top 5 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2018

Figure Global Top 10 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2018

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (%) (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Regions (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions in 2018

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

Table North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure USA Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure UK Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

Table South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Colombia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Table Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Egypt Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Nigeria Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure South Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Type (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type in 2018

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Type (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Type (2019-2024)

Figure Global Crizotinib Revenue Growth Rate (2014-2019)

Figure Global Ceritinib Revenue Growth Rate (2014-2019)

Figure Global Alectinib Revenue Growth Rate (2014-2019)

Figure Global Brigatinib Revenue Growth Rate (2014-2019)

Figure Global Lorlatinib Revenue Growth Rate (2014-2019)

Figure Global Other Revenue Growth Rate (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application in 2018

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Application (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Application (2019-2024)

Figure Global Squamous Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Adenocarcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Large Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate Forecast (2019-2024)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Forecast by Regions (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share Forecast by Regions (2019-2024)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Licence Rights

Single User License - This is a single user license, allowing one specific user access to the product. The report will be emailed to you. The report is sent in PDF format.

Multi User License- allowing 1-20 people access to the product. The report will be emailed to you. The report is sent in PDF format and Excel Data. What's more, the comany can use the data, table, picture and figure on the report.

Corporate User License- This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish toreceive the hard copy version of this report.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Pfizer

Novartis

Chugai Pharmaceutical (Hoffmann-La Roche group)

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Beacon Pharma Limited

Drug International Limted

Incepta Pharmaceuticals

Company Profile

Company Profile Title

Scope of the Report:

The global Targeted Drug ALK Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug ALK Inhibitors for NSCLC.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Targeted Drug ALK Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug ALK Inhibitors for NSCLC market by product type and applications/end industries.

Market Segment by Companies, this report covers

Pfizer

Novartis

Chugai Pharmaceutical (Hoffmann-La Roche group)

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Beacon Pharma Limited

Drug International Limted

Incepta Pharmaceuticals

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Crizotinib

Ceritinib

Alectinib

Brigatinib

Lorlatinib

Other

Market Segment by Applications, can be divided into

Squamous Cell Carcinoma of NSCLC

Adenocarcinoma of NSCLC

Large Cell Carcinoma of NSCLC

READ MORE

Scope

Table of Contents

1 Targeted Drug ALK Inhibitors for NSCLC Market Overview

1.1 Product Overview and Scope of Targeted Drug ALK Inhibitors for NSCLC

1.2 Classification of Targeted Drug ALK Inhibitors for NSCLC by Types

1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)

1.2.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Types in 2018

1.2.3 Crizotinib

1.2.4 Ceritinib

1.2.5 Alectinib

1.2.6 Brigatinib

1.2.7 Lorlatinib

1.2.8 Other

1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application

1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Squamous Cell Carcinoma of NSCLC

1.3.3 Adenocarcinoma of NSCLC

1.3.4 Large Cell Carcinoma of NSCLC

1.4 Global Targeted Drug ALK Inhibitors for NSCLC Market by Regions

1.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug ALK Inhibitors for NSCLC Status and Prospect (2014-2024)

1.5 Global Market Size of Targeted Drug ALK Inhibitors for NSCLC (2014-2024)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.3 Chugai Pharmaceutical (Hoffmann-La Roche group)

2.3.1 Business Overview

2.3.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.4 ARIAD Pharmaceuticals (Takeda)

2.4.1 Business Overview

2.4.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.5 Genvio Pharma Limited

2.5.1 Business Overview

2.5.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.6 Beacon Pharma Limited

2.6.1 Business Overview

2.6.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.7 Drug International Limted

2.7.1 Business Overview

2.7.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

2.8 Incepta Pharmaceuticals

2.8.1 Business Overview

2.8.2 Targeted Drug ALK Inhibitors for NSCLC Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

3 Global Targeted Drug ALK Inhibitors for NSCLC Market Competition, by Players

3.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Targeted Drug ALK Inhibitors for NSCLC Players Market Share

3.2.2 Top 10 Targeted Drug ALK Inhibitors for NSCLC Players Market Share

3.3 Market Competition Trend

4 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Regions

4.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Regions

4.2 North America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.3 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.5 South America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

5.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

5.2 USA Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5.3 Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

5.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

6.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

6.2 Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.3 UK Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.4 France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.5 Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

6.6 Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

7.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

7.2 China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.3 Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.4 Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.5 India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries

8.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

8.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

8.4 Colombia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Targeted Drug ALK Inhibitors for NSCLC by Countries

9.1 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

9.2 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.3 UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.4 Egypt Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.5 Nigeria Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

9.6 South Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

10 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Type

10.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)

10.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type (2019-2024)

10.3 Crizotinib Revenue Growth Rate (2014-2024)

10.4 Ceritinib Revenue Growth Rate (2014-2024)

10.5 Alectinib Revenue Growth Rate (2014-2024)

10.6 Brigatinib Revenue Growth Rate (2014-2024)

10.7 Lorlatinib Revenue Growth Rate (2014-2024)

10.8 Other Revenue Growth Rate (2014-2024)

11 Global Targeted Drug ALK Inhibitors for NSCLC Market Segment by Application

11.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)

11.2 Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Application (2019-2024)

11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)

11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)

11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)

12 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)

12.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Forecast (2019-2024)

12.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Regions (2019-2024)

12.3 North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.4 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.6 South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source


List Of Table

List of Tables and Figures

Figure Targeted Drug ALK Inhibitors for NSCLC Picture

Table Product Specifications of Targeted Drug ALK Inhibitors for NSCLC

Table Global Targeted Drug ALK Inhibitors for NSCLC and Revenue (Million USD) Market Split by Product Type

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Types in 2018

Figure Crizotinib Picture

Figure Ceritinib Picture

Figure Alectinib Picture

Figure Brigatinib Picture

Figure Lorlatinib Picture

Figure Other Picture

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Application (2014-2024)

Figure Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Applications in 2018

Figure Squamous Cell Carcinoma of NSCLC Picture

Figure Adenocarcinoma of NSCLC Picture

Figure Large Cell Carcinoma of NSCLC Picture

Table Global Market Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Comparison by Regions 2014-2024

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (2014-2024)

Table Pfizer Basic Information, Manufacturing Base and Competitors

Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Novartis Basic Information, Manufacturing Base and Competitors

Table Novartis Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Basic Information, Manufacturing Base and Competitors

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table ARIAD Pharmaceuticals (Takeda) Basic Information, Manufacturing Base and Competitors

Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Genvio Pharma Limited Basic Information, Manufacturing Base and Competitors

Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Beacon Pharma Limited Basic Information, Manufacturing Base and Competitors

Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Drug International Limted Basic Information, Manufacturing Base and Competitors

Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Incepta Pharmaceuticals Basic Information, Manufacturing Base and Competitors

Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Type and Applications

Table Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Players (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2017

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2018

Figure Global Top 5 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2018

Figure Global Top 10 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2018

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate (%) (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Regions (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Regions in 2018

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

Table North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure USA Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure UK Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Countries (2014-2019)

Table South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Colombia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Countries (2014-2019)

Table Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries (2014-2019)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Countries in 2018

Figure Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Egypt Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure Nigeria Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Figure South Africa Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) by Type (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type in 2018

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Type (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Type (2019-2024)

Figure Global Crizotinib Revenue Growth Rate (2014-2019)

Figure Global Ceritinib Revenue Growth Rate (2014-2019)

Figure Global Alectinib Revenue Growth Rate (2014-2019)

Figure Global Brigatinib Revenue Growth Rate (2014-2019)

Figure Global Lorlatinib Revenue Growth Rate (2014-2019)

Figure Global Other Revenue Growth Rate (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2014-2019)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application in 2018

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Application (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Application (2019-2024)

Figure Global Squamous Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Adenocarcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Large Cell Carcinoma of NSCLC Revenue Growth Rate (2014-2019)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) and Growth Rate Forecast (2019-2024)

Table Global Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Forecast by Regions (2019-2024)

Figure Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share Forecast by Regions (2019-2024)

Figure North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Figure Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Forecast (2019-2024)

Single User License - This is a single user license, allowing one specific user access to the product. The report will be emailed to you. The report is sent in PDF format.

Multi User License- allowing 1-20 people access to the product. The report will be emailed to you. The report is sent in PDF format and Excel Data. What's more, the comany can use the data, table, picture and figure on the report.

Corporate User License- This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish toreceive the hard copy version of this report.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Pfizer

Novartis

Chugai Pharmaceutical (Hoffmann-La Roche group)

ARIAD Pharmaceuticals (Takeda)

Genvio Pharma Limited

Beacon Pharma Limited

Drug International Limted

Incepta Pharmaceuticals